Skip to content

C4 Therapeutics, Inc.

CCCC

CIK 0001662579

← back to feed
Revenue (TTM)
$31.08M
+1.0% YoY Q1 May 2026
Net Income (TTM)
−$109.64M
+0.3% YoY Q1 May 2026
EPS Diluted (TTM)
−$1.38
+16.4% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-385.6%
Q1 May 2026
Net Margin
-352.7%
Q1 May 2026
Free Cash Flow (TTM)
−$115.13M
Q1 May 2026
Cash
$61.27M
Q1 May 2026
Total Debt
$0
Q1 May 2026
Shares Outstanding
110.57M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings